Summary of findings 2. Combination versus single‐agent chemotherapy for advanced gastric cancer.
Combination versus single‐agent chemotherapy for advanced gastric cancer | ||||||
Patient or population: people with advanced gastric cancer
Settings: outpatient clinics participating in international multicentre studies
Intervention: combination Control: single‐agent chemotherapy | ||||||
Outcomes | Illustrative comparative risks* (95% CI) | Relative effect (95% CI) | No of Participants (studies) | Quality of the evidence (GRADE) | Comments | |
Assumed risk | Corresponding risk | |||||
Single‐agent chemotherapy | Combination | |||||
Overall survival | Study population | HR 0.84 (0.79 to 0.89) | 4447 (23) | ⊕⊕⊕⊝ moderate1 | Weighted average of median survival durations from included studies | |
|
|
|||||
Tumour response | Study population | OR 2.30 (1.94 to 2.72) | 2833 (18) | ⊕⊕⊕⊕ high1 | ||
226 per 1000 | 402 per 1000 (361 to 442) | |||||
Moderate | ||||||
231 per 1000 | 409 per 1000 (368 to 450) | |||||
Time to progression | Study population | HR 0.69 (0.55 to 0.87) | 720 (4) | ⊕⊕⊕⊝ moderate1 | Weighted average of median survival durations from included studies | |
2.8 months | 4.1 months | |||||
Treatment‐related death | Study population | OR 1.64 (0.83 to 3.24) | 3876 (18) | ⊕⊕⊝⊝ moderate2 | ||
5 per 1000 | 9 per 1000 (4 to 17) | |||||
Moderate | ||||||
0 per 1000 | 0 per 1000 (0 to 0) | |||||
*For time‐to‐event outcomes, e.g. overall survival, the assumed and corresponding risks were obtained by calculating the weighted average of the median survival durations reported in included studies. For dichotomous outcomes, the assumed and corresponding risks (and their 95% confidence interval) are based on proportions of events in the control and intervention groups respectively. CI: Confidence interval; OR: Odds ratio; HR: Hazard ratio; | ||||||
GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate. |
1 Downgraded by one level for risk of bias. 2 Downgraded by two levels for serious imprecision.